top of page


We are proud to offer cPass, the first FDA-authorised test for neutralising antibodies against SARS-CoV-2 (under EUA).

cPass delivers reliable data to help estimate individual immunity against SARS-CoV-2.

Contact us today for more information.


Why measure levels of immunity to COVID-19?

By estimating immunity or measuring the real-world effectiveness of vaccination programs, we can better manage public health risks and guide the reopening of our societies.

Individual Booster Requirements

Measuring neutralising antibody levels with cPass™ may determine how long immunity lasts and can help inform decision making about booster requirements.

and elderly

In immuno-compromised individuals, an effective vaccination strategy together with cPass™ may offer an added level of assurance to those most vulnerable.

Risk Stratification

An understanding of infection and illness risk empowers effective decision making. cPass™ may help inform public health policy, business management and personal peace of mind.

IBH has distribution rights to commercialise, launch and supply cPass™ and cPass Express™ in Australia, New Zealand, South Pacific Islands, Bangladesh, Philippines and Indonesia

International Travel

Concerns related to cross border spread of COVID-19 can possibly be minimised using cPass™. Travel decisions may be more confidently informed when venturing into areas with increased health and safety risks.


Neutralising antibodies:
an important biomarker
of immunity.

cPass™, the first FDA-authorised test for neutralising antibodies (NAb) against the SARS-CoV-2 virus.

cPass™ directly measures NAb, a type of antibody produced by the immune system against SARS-CoV-2.

NAb directly block the SARS-CoV-2 virus from entering human cells, making them the most important biomarker of immunity.

Contact us to learn more about cPass™.

bottom of page